Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Pharmacy · Neurology, PharmacyMedium impact

08.02.43, Nipocalimab-aahu (Imaavy)

Act
by Dec 31, 2025
Effective date
Jan 1, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross has issued a new pharmacy policy (08.02.43) effective January 1, 2026, establishing coverage criteria for nipocalimab-aahu (Imaavy) in the treatment of generalized myasthenia gravis (gMG) in patients 12 years and older. Coverage requires documented contraindication or nonresponse to Vyvgart IV or Rystiggo, antibody positivity, MGFA classification II-IV, MG-ADL score ≥6, and stable baseline MG therapy. Billing teams must implement prior authorization and documentation requirements for HCPCS code J9256 claims.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Dec 31, 2025 · 5 steps
01Billing team must implement prior authorization requirements for HCPCS code J9256 (nipocalimab-aahu).
02Update billing system to require documentation of: (1) documented contraindication or nonresponse to Vyvgart IV or Rystiggo, (2) AChR/MuSK/LRP4 antibody positivity OR MGFA Class II-IV gMG diagnosis, (3) MG-ADL score ≥6, and (4) stable baseline MG therapy (AChE inhibitors, steroids, or NSISTs).
03Create prior authorization checklist for providers and front desk staff.
04Update EMR templates to capture all required criteria.
05All claims for J9256 submitted without complete documentation will be denied effective January 1, 2026.

Codes mentioned

J9256G70.00G70.01

Original notice

08.02.43, Nipocalimab-aahu (Imaavy)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.187, Nipocalimab-aahu (Imaavy)MediumEffective Jan 1, 2026 · PharmacyMA05.001l, High-Frequency Chest Wall Oscillation DevicesMediumEffective Nov 17, 2025 · Medical Policy05.00.14s, High-Frequency Chest Wall Oscillation DevicesLowEffective Nov 17, 2025 · Medical PolicyMA08.164a, Rozanolixizumab-noli (Rystiggo)LowNo effective date · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesNeurologyPharmacyCode J9256Code G70.00Code G70.01

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account